Roxithromycin
产品说明书
 |
同义名 : | RU-28965; RU 965; Rulide; Roxithromycinum |
| CAS号 : | 80214-83-1 | |
| 货号 : | A131067 | |
| 分子式 : | C41H76N2O15 | |
| 纯度 : | 95% | |
| 分子量 : | 837.05 | |
| MDL号 : | MFCD00214389 | |
| 存储条件： |
Pure form Sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(125.44 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Roxithromycin is a semi-synthetic 14-membered-ring macrolide antibiotic, the in-vitro activity of roxithromycin is well documented and similar to that of other macrolide antibiotics. Roxithromycin is active against gram-positive and gram-negative cocci, gram-positive bacilli and some gram-negative bacilli, but has no significant effect on the predominant faecal flora[3]. Roxithromycin is very well tolerated with an overall incidence of adverse events of approximately 4%. Roxithromycin has proven clinical efficacy in upper and lower respiratory infections, skin and soft tissue infections, urogenital infections and orodental infections, and appears to be as effective as more established treatments including erythromycin, amoxicillin/clavulanic acid and cefaclor[4]. Macrolide antibiotics show antibacterial and anti-inflammatory efficacy in otitis media with effusion[5]. The increasing of RAGE (Receptor of Advanced glycation end products) in asthmatic rats are positively correlated with airway inflammation and airway remodeling. Roxithromycin may inhibit the development of asthma by reducing the expression of RAGE[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02735707 | Community-Acquired Pneumonia | Phase 4 | Recruiting | June 2022 | - |
| NCT03571230 | Helicobacter Pylori Infection ... 展开 >> Antimicrobial Susceptibility Testing 收起 << | Phase 4 | Not yet recruiting | January 30, 2020 | China, Shandong ... 展开 >> Xiuli Zuo Not yet recruiting Jinan, Shandong, China Contact: Xiuli Zuo, PhD,MD 15588818685 ext 053188369277 zuoxiuli@sina.com Sub-Investigator: Jing Liu, MD Sub-Investigator: Chaoran Ji, MD 收起 << |
| NCT02819570 | Premature Rupture of Membrane | Phase 4 | Unknown | December 2017 | Israel ... 展开 >> Galil Medical Center Recruiting Nahariyya, Israel Contact: Maya Wolf, MD 972-507887800 homesickid@yahoo.com 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.19mL 0.24mL 0.12mL |
5.97mL 1.19mL 0.60mL |
11.95mL 2.39mL 1.19mL |
| 参考文献 |
|---|
|
[6]Gu XF, Chen HJ, Chen XM, et al. Zhonghua Yi Xue Za Zhi. 2019;99(32):2542‐2546 |